Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice

Sponsor
Bayer
Study ID
NCT04137120
Status
Completed

Conditions

  • Retinal Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The study aims to collect data on the safety and use of intravitreal aflibercept injections into the eye for the treatment of eye disorders that cause blurred vision or a blind spot due to abnormal or blocked blood vessels. Data will be collected from patients who are being treated for such eye disorders in Mexican routine clinical practice.

Key Dates

Start date
Feb 19, 2021
Status verified
Feb 2023
Primary completion
Aug 17, 2022
Completion
Feb 1, 2023

Study Design

Enrollment
73 participants (actual)

Arms

  • Arm: Patients_Ocular disease
    Adult patients treated for wet age-related macular degeneration (wAMD), or diabetic macular edema (DME), or macular edema secondary to central retinal vein occlusion (CRVO), or macular edema secondary to branch retinal vein occlusion (BRVO) or myopic choroidal neovascularization (mCNV) in routine clinical practice in Mexico (overall cohort)

Primary Outcome Measure

Number of ocular adverse events [ Time Frame: Up to 12 months ]

Related Studies